Search Results

open access

Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Description: This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Date: September 10, 2001
Creator: Redhead, C. Stephen
Partner: UNT Libraries Government Documents Department
open access

Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Description: This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Date: October 3, 2002
Creator: Redhead, C. Stephen
Partner: UNT Libraries Government Documents Department
open access

Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Description: This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Date: January 3, 2003
Creator: Redhead, C. Stephen
Partner: UNT Libraries Government Documents Department
open access

Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Description: This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Date: June 11, 2003
Creator: Redhead, C. Stephen
Partner: UNT Libraries Government Documents Department
open access

Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Description: This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Date: March 10, 2004
Creator: Redhead, C. Stephen
Partner: UNT Libraries Government Documents Department
open access

The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents

Description: This record provides information about The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents. Congressional interests in the cost of Pharmaceuticals have focused attention on several areas where the federal government has policies and programs.
Date: November 25, 2002
Creator: Schacht, Wendy H. & Thomas, John R.
Partner: UNT Libraries Government Documents Department
open access

The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents

Description: This record provides information about The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents. Congressional interests in the cost of Pharmaceuticals have focused attention on several areas where the federal government has policies and programs.
Date: January 16, 2003
Creator: Schacht, Wendy H. & Thomas, John R.
Partner: UNT Libraries Government Documents Department
open access

The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents

Description: This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on the Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
Date: May 8, 2003
Creator: Schacht, Wendy H. & Thomas, John R.
Partner: UNT Libraries Government Documents Department
open access

The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents

Description: This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
Date: June 23, 2003
Creator: Schacht, Wendy H. & Thomas, John R.
Partner: UNT Libraries Government Documents Department
open access

The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents

Description: This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
Date: June 30, 2003
Creator: Schacht, Wendy H. & Thomas, John R.
Partner: UNT Libraries Government Documents Department
open access

The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents

Description: This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
Date: July 15, 2003
Creator: Schacht, Wendy H. & Thomas, John R.
Partner: UNT Libraries Government Documents Department
open access

The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents

Description: This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
Date: September 17, 2003
Creator: Schacht, Wendy H. & Thomas, John R.
Partner: UNT Libraries Government Documents Department
open access

The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents

Description: This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
Date: October 9, 2003
Creator: Schacht, Wendy H. & Thomas, John R.
Partner: UNT Libraries Government Documents Department
open access

The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents

Description: This record provides information about The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents. Congressional interests in the cost of Pharmaceuticals have focused attention on several areas where the federal government has policies and programs.
Date: January 5, 2004
Creator: Schacht, Wendy H. & Thomas, John R.
Partner: UNT Libraries Government Documents Department
open access

The Cost of Prescription Drugs for the Uninsured Elderly and Legislative Approaches

Description: The purpose of this report is to explain why many of those who are least able to afford high drug costs are those who are most frequently charged the most. This report describes the basic economic theory underlying price differentiation and, in the context of the pharmaceutical market, analyzes the role and behavior of pharmacy benefit managers (PBMs), pharmaceutical manufacturers, and retail pharmacies, respectively. It also looks at a number of the criticisms that have been made of the practi… more
Date: January 16, 2001
Creator: Library of Congress. Congressional Research Service. Resources, Science, and Industry Division.
Partner: UNT Libraries Government Documents Department
Back to Top of Screen